Midkine 的阳性表达预示着可切除的原发性混合性肝细胞胆管细胞癌早期复发和预后不良。
Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma.
机构信息
Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung, 833, Taiwan.
Chang Gung University College of Medicine, Kaohsiung, Taiwan.
出版信息
BMC Cancer. 2018 Feb 27;18(1):227. doi: 10.1186/s12885-018-4146-7.
BACKGROUND
Post-surgical prognosis is usually poor for combined hepatocellular cholangiocarcinoma (CHCC-CC), a rare primary liver cancer. Although midkine (MK) is a prognostic biomarker for several known cancers, it is not known whether it can be used as such in resectable CHCC-CC. This study examined whether MK expression can predict recurrence and survival in patients with resectable CHCC-CC.
METHODS
We retrospectively enrolled 52 patients with resectable CHCC-CC who had received curative hepatic resections. MK expression was assessed in post-surgical immunohistochemical studies of specimens in paraffin blocks. Clinical outcomes were analyzed from medical records.
RESULTS
Two-year disease-free and three-year overall survival rates were 42.1% and 44.6%. MK was expressed in 30 patients. Univariate analysis showed patients positively expressing MK had a significantly poorer 2-year disease free and three-year overall survival. Multivariate analysis found positive MK expression independently predicted recurrence.
CONCLUSIONS
Positive expression of MK predicts poor prognosis in patients with resectable CHCC-CC.
背景
混合性肝细胞胆管细胞癌（CHCC-CC）是一种罕见的原发性肝癌，其术后预后通常较差。虽然中期因子（MK）是几种已知癌症的预后生物标志物，但尚不清楚其是否可用于可切除的 CHCC-CC。本研究旨在探讨 MK 表达能否预测可切除 CHCC-CC 患者的复发和生存情况。
方法
我们回顾性纳入了 52 例接受根治性肝切除术的可切除 CHCC-CC 患者。在石蜡块的术后免疫组织化学研究中评估了 MK 表达。从病历中分析临床结果。
结果
2 年无病生存率和 3 年总生存率分别为 42.1%和 44.6%。MK 在 30 例患者中表达。单因素分析显示，MK 阳性表达的患者 2 年无病生存率和 3 年总生存率显著较低。多因素分析发现 MK 阳性表达独立预测了复发。
结论
MK 阳性表达可预测可切除 CHCC-CC 患者的不良预后。
Zotero 插件